Allergan enters billion-dollar deal for MedImmune's Crohn's/colitis candidate; AZ regains all rights
AstraZeneca's MedImmune LLC granted Allergan PLC exclusive global rights to develop and sell its MEDI2070, an interleukin-23 monoclonal antibody in Phase IIb for Crohn's disease and entering Phase II ulcerative colitis and related disorders.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com